Atsena Therapeutics
Melissa M Endejann has an extensive background in quality assurance within the pharmaceutical industry, holding various titles from Associate Director to Vice President of Quality. Melissa M's experience spans across different companies such as Atsena Therapeutics, SpringWorks Therapeutics, Melinta Therapeutics, Cempra Pharmaceuticals, and more. With a Bachelor's degree in Biology from the University of North Carolina at Chapel Hill, Melissa has a strong foundation in the field of life sciences.
This person is not in any teams
This person is not in any offices
Atsena Therapeutics
Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness. They have an ongoing Phase I/II clinical trial evaluating a potential therapy for one of the most common causes of blindness in children. Their additional pipeline of leading preclinical assets is powered by an adeno-associated virus (AAV) technology platform tailored to overcome significant hurdles presented by inherited retinal disease.